共 50 条
- [1] Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLCMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Manickavasagar, ThubeenaStavraka, CharaAnam, KaiserComa, SilviaChowdhury, SanjibPachter, Jonathan A.Parker, TomParmar, MonaFinneran, LauraHall, EmmaSpicer, JamesMinchom, AnnaBanerji, Udai
- [2] Preclinical evaluation of avutometinib (VS-6766; RAF/MEK clamp) in combination with EGFR inhibition in colorectal cancer patient- derived xenograft (PDX) models harboring KRAS mutationsCANCER RESEARCH, 2023, 83 (07)Wang, ChongkaiComa, SilviaPachter, JonathanFakih, Marwan
- [3] In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancerCANCER RESEARCH, 2023, 83 (07)McNamara, BlairDemirkiran, CemBellone, StefaniaMutlu, LeventZipponi, MargheritaVerzosa, Miguel S.Harold, JustinHartwich, Tobias M.Altwerger, GaryRatner, ElenaHuang, GloriaClark, MitchellAndikyan, VaagnAzodi, MasoudSchwartz, Peter E.Dottino, PeterSantin, Alessandro D.
- [4] A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Camidge, D. RossReuss, Joshua E.Spira, Alexander I.Janne, Pasi A.Rehman, MuneebPachter, Jonathan A.Patrick, GloriaDenis, Louis J.Spigel, David R.
- [5] A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC.CANCER RESEARCH, 2021, 81 (13)Krebs, Matthew G.Shinde, RajivRahman, Rozana AbdulGrochot, RafaelLittle, MartinKing, JennyKitchin, JosephParmar, MonaTurner, AlisonMahmud, MuneebYap, ChristinaTunariu, NinaLopez, JuanitaDe Bono, Johann S.Banerji, UdaiMinchom, Anna
- [6] A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Camidge, D. RossPachter, JonathanKoustenis, AndrewPatrick, GloriaSpigel, David R.
- [7] Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Minchom, Anna RachelPerez, Vicky SanchezMorton, CienneManickavasagar, ThubeenaNintos, GeorgeLai-Kwon, Julia ElizabethGuo, ChristinaTunariu, NinaParker, TomProut, TobyParmar, MonaTurner, Alison JoanneFinneran, LauraHall, EmmaPachter, Jonathan A.Denis, Louis J.Spicer, James F.Banerji, Udai
- [8] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Govindan, RamaswamyAwad, Mark M.Gadgeel, Shirish M.Pachter, Jonathan A.Patrick, GloriaDenis, Louis J.
- [9] Impact of EMT status on the efficacy of the combination of RAF/MEK clamp with FAK inhibitor in KRAS-mutated lung cancerCANCER SCIENCE, 2025, 116 : 1294 - 1294Yoshimura, AkihiroHorinaka, ManoYaoi, TakeshiOno, HisakoItoh, KyokoYamada, TadaakiTakayama, KoichiSakai, Toshiyuki
- [10] THE EVALUATION OF SELUMETINIB A MEK-INHIBITOR WITH AND WITHOUT THE ADDITION OF ERLOTINIB IN KRAS MUTATED NON-SMALL CELL LUNG CANCERANNALS OF ONCOLOGY, 2013, 24 : 15 - 15Carter, C.Rajan, A.Khozin, S.Thomas, A.Lopez-Chavez, A.Brzezniak, C.Doyle, L.Keen, C.Manu, M.Raffeld, M.Giaccone, G.